NBIX:
The current market price is 134.66, showing no percentage change from the previous close.
Support and Resistance Levels
Current support levels are 134.66, 134.66, and 134.66. Current resistance levels are 134.66, 134.66, and 134.66. The pivot point is 134.66.
Indicators
The RSI is at 100 indicating overbought conditions. ATR is 0, ADX data unavailable. Parabolic SAR is at 134.66. All SMAs and EMAs are at 134.66.
Market Sentiment
The price is at the pivot point of 134.66, so no clear bullish or bearish trend exists. Watch for emerging indicators.
NBIX Signals & Technical Analysis
Last Updated: <% indicators.interval.updated|date:'MMM d, y h:mm:ss a' %>
Neurocrine Biosciences Inc. (NASDAQ: NBIX) is a biopharmaceutical company based in the United States that specializes in the development and commercialization of innovative treatments for neurological and endocrine disorders. Founded in 1992, Neurocrine is dedicated to improving the lives of patients through cutting-edge research and a commitment to advancing the science of medicine. The company's proprietary products and pipeline candidate focus on addressing critical unmet medical needs in a variety of therapeutic areas, including disorders related to the brain and hormonal systems.
Market Position
Neurocrine Biosciences has established itself as a leader in the biopharmaceutical industry, particularly in the field of neurology and endocrinology. The company's flagship product, Ingrezza (valbenazine), was approved by the FDA for the treatment of tardive dyskinesia, positioning Neurocrine as a pioneer in this therapeutic area. With a robust pipeline that includes compounds targeting Parkinson's disease, epilepsy, and other central nervous system disorders, Neurocrine is well-positioned to capitalize on the growing demand for advanced treatment options. The company maintains strategic partnerships and collaborations with various research institutions and organizations, enhancing its capabilities and market reach.
Key Financial and Industry Highlights
Neurocrine Biosciences has demonstrated strong financial performance, with significant revenue growth driven by its product portfolio, particularly from Ingrezza. The company reported impressive earnings results, reflecting its operational efficiency and commitment to R&D investment. Neurocrine's solid financial footing allows for continued investment in innovative therapies and the exploration of new treatment options. As the biopharmaceutical landscape evolves, Neurocrine remains committed to addressing pivotal healthcare challenges, with a focus on delivering breakthrough therapies that significantly enhance patient outcomes. The growing prevalence of neurological disorders presents a substantial opportunity for Neurocrine, reinforcing its market position as a key player in the biopharmaceutical sector.
<% (signals.list.current.rate).substr(0,7) %>
<% signal.analyst %>
